Low dose RLS103
Phase 1Small molecule
Low dose RLS103 is one of 53 small molecule programs targeting Photosensitive Epilepsy. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
47 competitors in Social Anxiety Disorder
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Vraylar
AbbVieApproved
Lexapro
AbbVieApproved
Paxil
SSebela Pharmaceuticals Development LLC
Approved
Zoloft
VViatris Specialty LLC
Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Effexor
WWyeth-Lederle Vaccines
Approved
Klonopin
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Transderm Scop
BBaxter Healthcare Corporation
Approved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Low dose RLS103. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- RReceptor Life Sciences